摘要
胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)类似物具有独特的血糖浓度依赖性的控制血糖效果,为2型糖尿病患者提供了新的用药选择。新药研发多以人体内源性GLP-1及其天然类似物Exendin-4为基础。本文对GLP-1和Ex-endin-4的结构、重要位点、改构策略、修饰方式、新剂型以及GLP-1类似物新药研发的进展作一综述。
Because of their special blood glucose concentration-dependent effect in controlling blood glucose,glucagon-like peptide-1（GLP-1） analogues provide a new choice for the patients with type 2 diabetes mellitus（T2DM）.Most developments of new drugs are based on the endogenous human GLP-1 and their natural analogue Exendin-4.This paper reviews the structures,important sites,remodeling strategies,modification mode and new forms of GLP-1 and Exendin-4 as well as GLP-1 analogues as new drugs.
出处
《中国生物制品学杂志》
CAS
CSCD
2011年第7期866-868,872,共4页
Chinese Journal of Biologicals
